Prandial Insulin Updates for the Diabetes Specialist

Sunday, September 24, 2017 | 11:55 AM - 1:05 PM

Chicago Marriott Downtown Magnificent Mile 

This course is a live CME-certified ancillary symposium presented at Clinical Endocrinology Update 2017, held in Chicago, Illinois, September 23-25, 2017. CEU 2017 ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC).

This activity is supported by an educational grant from Novo Nordisk.

Learning Objectives

Upon completion of this activity, participants will:
Have increased knowledge regarding the
        – Safety and efficacy data of emerging prandial injectable insulin products
        – Differences of emerging prandial injectable insulin products compared to traditional prandial               injectable insulin therapies

Greater competence related to
        – Clinical considerations for using prandial insulin in patients with type 1 and type 2 diabetes

Improved performance related to
        – The appropriate use of prandial insulin as a next step in an individualized diabetes                                management plan

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Medical Knowledge
Practice-based Learning and Improvement
Systems-based Practice
Topic Area: 
Bone and Calciotropic Hormones
General Endocrinology
Thyroid/HPT Axis
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 1.00 ABIM MOC
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation
Course opens: 
09/24/2017
Course expires: 
05/01/2018
Rating: 
0

In this 60-minute live symposium, 3 experts will review the role of current prandial insulins in the treatment of diabetes. In addition, they will discuss emerging prandial insulins and how they may offer advantages over traditional prandial injectables. Realistic patient case scenarios will also be used to demonstrate best practices for the addition of prandial insulin.

Chicago Marriott Downtown Magnificent Mile
Chicago, IL
United States

Program Director:
Carol H. Wysham, MD
Clinical Professor of Medicine
University of Washington
School of Medicine
Rockwood Center for Diabetes and Endocrinology
Spokane, Washington

Faculty:

David Baldwin, Jr., MD
Professor of Medicine
Section of Endocrinology
Rush University Medical Center
Chicago, Illinois

Janet B. McGill, MD
Professor of Medicine
Division of Endocrinology
Metabolism and Lipid Research
Washington University School of Medicine
St. Louis, Missouri

Disclosure Policy
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Carol H. Wysham, MD: Consultant, Abbott, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, Sanofi; Speaker, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Insulet, Janssen, Novo Nordisk, Sanofi

The following faculty reported no relevant financial relationships:
David Baldwin, Jr., MD


The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:
Amy Rothberg, MD


The following SPC members reported relevant financial relationships:
Zahid Ahmad, MD: Research Support, Regeneron, FH Foundation; Consultant, Regeneron; Speaker, Amgen, Genzyme, Sanofi
Andrew Ahmann, MD: Research Support, DexCom, Lexicon, Medtronic, Novo Nordisk; Consultant, Dexcom, Novo Nordisk, Trividia Health
Giuseppe Barbesino, MD: Spouse, employee of Genzyme
John Carmichael, MD: Research Support, Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker, Novartis; Advisory Board, Pfizer, Chiasma, Ionis Pharmaceuticals
Natalie Cusano, MD: Research Support, Shire; Speaker, Shire
Joan Han, MD: Research Support, Rhythm Pharmaceutical
Steven T. Harris, MD: Ad hoc consultant on Advisory Boards, Eli Lilly & Company, Merck, Radius Health; Speaker, Amgen, Eli Lilly & Company, Radius Health, Shire
Alan Kelly, MD: Speaker, Eli Lilly
Jonathan Purnell, MD: Advisor, Novo Nordisk
Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca /Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships:
Susmeeta Sharma, MD

Endocrine Society and Medscape, LLC staff associated with the development of content for this activity reported no relevant financial relationships.

DISCLAIMERS

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

PRIVACY AND CONFIDENTIALITY STATEMENT

The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

Click "Start" to complete meeting evaluation, claim CME, and print a certificate of attendance or certificate of participation

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  The Endocrine Society has achieved Accreditation with Commendation.  The Endocrine Society designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™ and 1 ABIM MOC Point.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 ABIM MOC
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation

Accreditation Period

Course opens: 
09/24/2017
Course expires: 
05/01/2018